EMEA-000980-PIP04-18
Key facts
Invented name |
Adcetris
|
Active substance |
Brentuximab vedotin
|
Therapeutic area |
Oncology
|
Decision number |
P/0327/2018
|
PIP number |
EMEA-000980-PIP04-18
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Takeda Pharma A/S
Tel. +44 2031168000 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|